Salubris Pharmaceuticals has presented positive Phase I data for its siRNA therapy, SAL0132 (GW906), targeting liver angiotensinogen (AGT) for the treatment of hypertension. The data indicate the candidate has the potential for durable, once-every-6-months dosing. In the study, a single subcutaneous injection reduced AGT protein levels by over 90%, with the effect maintained for at least nine months in the cohort receiving the second-lowest dose. Significant reductions in both systolic and diastolic blood pressure were also observed, with effects sustained for up to 6 months.

The candidate, in-licensed from Chinese compatriot Gowell Pharma, is designed to provide a long-acting treatment option that could improve patient adherence compared to daily medications. Salubris is currently conducting a Phase II trial in patients with primary hypertension. The data support the potential of SAL0132 to offer a new, convenient therapeutic approach for blood pressure management.

PharmCube's NextBiopharm® database shows that SAL0132 is the fourth-most advanced candidate among AGT-targeted RNAi therapies globally. Click here to request a free trial for NextBiopharm®.